Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Effects of Exo- and Endocannabinoids in Multiple Sclerosis

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandling

  2. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mads Ravnborg
  • Per Soelberg Sørensen
  • Magnus Andersson
  • Elisabeth G Celius
  • Peter J Jongen
  • Irina Elovaara
  • Emmanuel Bartholomé
  • Cris S Constantinescu
  • Karsten Beer
  • Ellen Garde
  • Bjørn Sperling
Vis graf over relationer
Interferon beta is commonly used to treat patients with relapsing-remitting multiple sclerosis; however, the treatment is only partially effective in reducing relapses and progression of disability. Corticosteroids are used to treat relapses in patients with multiple sclerosis. We therefore aimed to investigate the combination of cyclic methylprednisolone and interferon beta for the treatment of relapsing-remitting multiple sclerosis.
OriginalsprogEngelsk
TidsskriftLancet neurology
Vol/bind9
Udgave nummer7
Sider (fra-til)672-80
Antal sider9
ISSN1474-4422
DOI
StatusUdgivet - 1 jul. 2010

ID: 31051750